MarketCap
Facebook
X
Telegram
BioDelivery Sciences International Balance Sheet 2021-2008 | BDSI
Brief balance sheet overview of BioDelivery Sciences International
This overview follows the five latest available annual observations between 2017 and 2021.
Assets rose from $88.1 million to $324.6 million, a gain of +268.4%, while CAGR was about 38.5%. The balance sheet expanded rapidly.
Liabilities grew more slowly than assets: +72.6% versus +268.4%. Expansion relied more on equity, improving funding quality.
Equity accounts for 57.9% of assets. Against the initial 10.1%, the capital position looks resilient.
Cash exceeds interest-bearing debt, producing net debt of -$113.7 million. The balance sheet therefore carries a net cash position.
The cash reserve occupies 35.2% of the balance sheet, previously 24.1%. It is one marker of short-term resilience.
The balance sheet carries negative retained earnings of -$256 million. The figure may result from accumulated losses or an active capital return policy.
Overall picture
BioDelivery Sciences International's balance sheet looks resilient: assets are supported by substantial equity, while debt does not overwhelm financial flexibility.
Annual Balance Sheet BioDelivery Sciences International
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-114 M | -111 M | -63.1 M | 7.83 M | 26.5 M | -2.75 M | -61.4 M | -66.3 M | -11.3 M | -63.2 M | -10.8 M | - | - | - |
Long Term Debt |
219 K | 213 K | 540 K | 51.7 M | 47.7 M | 29.3 M | 22.2 M | 4.17 M | 11.8 M | - | - | - | - | - |
Long Term Debt Current |
336 K | 327 K | 281 K | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | 78.7 M | 59.1 M | 57.3 M | 53.1 M | 50.1 M | 43 M | 5.71 M | 13.8 M | 2.72 M | 1.65 M | - | - | - |
Total Current Liabilities |
82.4 M | 53 M | 54 M | 21.5 M | 26.1 M | 19.3 M | 28.1 M | 29.2 M | 25 M | 23.2 M | 17.9 M | 22.1 M | - | - |
Total Liabilities |
137 M | 132 M | 113 M | 78.8 M | 79.2 M | 69.4 M | 71.1 M | 34.4 M | 38.8 M | 26 M | 19.5 M | 23.8 M | - | - |
Deferred Revenue |
- | - | - | - | - | 1.72 M | 1.88 M | 6.77 M | 2.93 M | 7.99 M | 12.5 M | 12.5 M | - | - |
Retained Earnings |
-256 M | -341 M | -367 M | -351 M | -305 M | -310 M | -243 M | -206 M | -151 M | -93.9 M | -95.6 M | -72.2 M | - | - |
Total Assets |
325 M | 240 M | 183 M | 109 M | 88.1 M | 51.7 M | 103 M | 88.8 M | 38 M | 75.7 M | 23.6 M | 33.6 M | - | - |
Cash and Cash Equivalents |
114 M | 112 M | 63.9 M | 43.8 M | 21.2 M | 32 M | 83.6 M | 70.5 M | 23.2 M | 63.2 M | 10.8 M | 18.2 M | 23.9 M | 906 K |
Book Value |
188 M | 108 M | 69.8 M | 29.7 M | 8.88 M | -17.7 M | 31.7 M | 54.4 M | -812 K | 49.8 M | 4.12 M | 9.79 M | - | - |
Total Shareholders Equity |
188 M | 108 M | 69.8 M | 29.7 M | 8.88 M | -17.7 M | 31.7 M | 54.4 M | -812 K | 49.8 M | 4.12 M | 9.79 M | 14.5 M | -33.6 M |
All numbers in USD currency
Quarterly Balance Sheet BioDelivery Sciences International
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | - | - | 219 K | - | - | - | 213 K | - | - | - | 540 K | 615 K | 687 K | 755 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
- | - | - | - | 137 M | 133 M | 136 M | 133 M | 132 M | 132 M | 135 M | 120 M | 113 M | 106 M | 99.9 M | 82.1 M | 78.8 M | 79.9 M | 78.1 M | 74 M | 79.2 M | 70.6 M | 69.9 M | 69.4 M | 69.4 M | 70.9 M | 71 M | 70.5 M | 71.1 M | 52.7 M | 50 M | 32.6 M | 34.4 M | 46.9 M | 42 M | 38.4 M | 38.8 M | 39.5 M | 22.2 M | 22.1 M | 26 M | 43.3 M | 40.3 M | 35.1 M | 19.5 M | 22 M | 23 M | 19.5 M |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.72 M | 1.72 M | 1.72 M | 1.72 M | 1.92 M | 1.96 M | 1.64 M | 1.88 M | 7.24 M | 7.25 M | 7.08 M | 6.77 M | 843 K | 1.3 M | 1.92 M | 2.93 M | 4.07 M | 5.61 M | 7.23 M | 7.99 M | 22.7 M | 22.3 M | 18.7 M | 12.5 M | 12.5 M | 12.5 M | 12.5 M |
Retained Earnings |
- | - | - | - | -256 M | -320 M | -327 M | -336 M | -341 M | -351 M | -360 M | -362 M | -367 M | -366 M | -366 M | -355 M | -351 M | -344 M | -325 M | -316 M | -305 M | -289 M | -277 M | -262 M | -310 M | -294 M | -278 M | -262 M | -243 M | -253 M | -233 M | -214 M | -206 M | -188 M | -163 M | -156 M | -151 M | -139 M | -120 M | -107 M | -93.9 M | -103 M | -85 M | -88.8 M | -95.6 M | -91.5 M | -86.4 M | -95.6 M |
Total Assets |
- | - | - | - | 325 M | 256 M | 250 M | 242 M | 240 M | 228 M | 220 M | 197 M | 183 M | 174 M | 166 M | 110 M | 109 M | 116 M | 119 M | 75.4 M | 88.1 M | 89.4 M | 96.2 M | 108 M | 51.7 M | 65.8 M | 77.7 M | 90.3 M | 103 M | 72.4 M | 84.9 M | 82.5 M | 88.8 M | 101 M | 104 M | 103 M | 38 M | 50.6 M | 49.3 M | 61.8 M | 75.7 M | 43.9 M | 56.1 M | 46.4 M | 23.6 M | 30 M | 35.5 M | 23.6 M |
Cash and Cash Equivalents |
- | - | - | - | 114 M | 101 M | 120 M | 116 M | 112 M | 100 M | 91 M | 70.6 M | 63.9 M | 55.9 M | 57.2 M | 41.3 M | 43.8 M | 49.5 M | 55.7 M | 12.1 M | 21.2 M | 19.7 M | 27.5 M | 35.2 M | 32 M | 44.7 M | 57.5 M | 69.4 M | 83.6 M | 54.4 M | 67.7 M | 63.5 M | 70.5 M | 85.8 M | 78.4 M | 88.2 M | 23.2 M | 38.3 M | 37.4 M | 49.7 M | 63.2 M | 31.3 M | 43 M | 32.1 M | 10.8 M | 15.1 M | 21.2 M | 10.8 M |
Book Value |
- | - | - | - | 188 M | 123 M | 114 M | 109 M | 108 M | 95.9 M | 84.8 M | 76.6 M | 69.8 M | 67.9 M | 66.2 M | 27.5 M | 29.7 M | 35.6 M | 40.7 M | 1.35 M | 8.88 M | 18.9 M | 26.3 M | 38.2 M | -17.7 M | -5.1 M | 6.66 M | 19.8 M | 31.7 M | 19.7 M | 34.9 M | 49.8 M | 54.4 M | 54.1 M | 61.8 M | 64.6 M | -812 K | 11 M | 27.1 M | 39.7 M | 49.8 M | 559 K | 15.8 M | 11.3 M | 4.12 M | 7.98 M | 12.5 M | 4.12 M |
Total Shareholders Equity |
- | - | - | - | 188 M | 123 M | 114 M | 109 M | 108 M | 95.9 M | 84.8 M | 76.6 M | 69.8 M | 67.9 M | 66.2 M | 27.5 M | 29.7 M | 35.6 M | 40.7 M | 1.35 M | 8.88 M | 18.9 M | 26.3 M | 38.2 M | -17.7 M | -5.1 M | 6.66 M | 19.8 M | 31.7 M | 19.7 M | 34.9 M | 49.8 M | 54.4 M | 54.1 M | 61.8 M | 64.6 M | -812 K | 11 M | 27.1 M | 39.7 M | 49.8 M | 559 K | 15.8 M | 11.3 M | 4.12 M | 7.98 M | 12.5 M | 4.12 M |
All numbers in USD currency
Balance Sheet is a fundamental financial report of BioDelivery Sciences International, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
USA
Canada
China
Israel
France
Germany
Britain
Russia
Belgium
Cayman-islands
